oxybutynin and ADDH
oxybutynin has been researched along with ADDH in 8 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " Desmopressin in combination with a fixed dose anticholinergic has been shown to be useful in individuals who fail desmopressin monotherapy, but still fails to achieve success rates greater than 60%." | 5.43 | Evaluating use of higher dose oxybutynin in combination with desmopressin for refractory nocturnal enuresis. ( Berkenwald, A; Ellsworth, P; Pires, J, 2016) |
| " Combination therapy with desmopressin and oxybutynin is a feasible, safe and effective treatment for nocturnal enuresis in these children." | 5.12 | Treatment of nocturnal enuresis in children with attention deficit hyperactivity disorder. ( Abu-Arafeh, W; Chertin, B; Farkas, A; Koulikov, D; Mor, Y; Shenfeld, OZ, 2007) |
| " Desmopressin in combination with a fixed dose anticholinergic has been shown to be useful in individuals who fail desmopressin monotherapy, but still fails to achieve success rates greater than 60%." | 1.43 | Evaluating use of higher dose oxybutynin in combination with desmopressin for refractory nocturnal enuresis. ( Berkenwald, A; Ellsworth, P; Pires, J, 2016) |
Research
Studies (8)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Berkenwald, A | 1 |
| Pires, J | 1 |
| Ellsworth, P | 1 |
| Chertin, B | 1 |
| Koulikov, D | 1 |
| Abu-Arafeh, W | 1 |
| Mor, Y | 1 |
| Shenfeld, OZ | 1 |
| Farkas, A | 1 |
| Larkin, HD | 1 |
| Findling, RL | 1 |
| Dinh, S | 1 |
| Faraone, SV | 1 |
| Hammerness, PG | 1 |
| Wilens, TE | 1 |
| Reimherr, FW | 1 |
| Marchant, BK | 1 |
| Olsen, JL | 1 |
| Wender, PH | 1 |
| Robison, RJ | 1 |
| Keating, GM | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety/Tolerability of Methylphenidate Transdermal System (MTS) for Before-School Dysfunction in Children With Attention Deficit Hyperactivity Disorder (ADHD)[NCT00586157] | Phase 4 | 36 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD[NCT00506285] | Phase 3 | 92 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Efficacy Defined as Change From Baseline on Investigator and Parental/Self-report Based Rating Scales and Questionnaires
"The questionnaire includes two a sections, a clinician rated 20-item scale and a 14-item self-report section completed collaboratively by child and parent/guardian.~Units on the clinician rated scale range from 0-3 on a scale of severity, with 0 being the least severe item score and 3 being the most severe. Units on the self-report section ranged from 0-2 on a scale of severity, with 0 being the least severe item score and 2 being the most severe. The possible range of scores for the questionnaire is 88" (NCT00586157)
Timeframe: Baseline and 4 weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| MTS (Drug A) | 12.76 |
| Placebo | 31.37 |
Efficacy Defined as Change From Baseline on the Investigator Rated DSM-IV Based ADHD Rating Scale, During the AM.
Units on a scale range from 0-3 on a scale of severity, with 0 being the least severe item score and 3 being the most severe. The possible range of scores for the scale is 0 (least severe) to 54 (most severe). (NCT00586157)
Timeframe: Baseline and 4 weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| MTS (Drug A) | 10.03 |
| Placebo | 23.22 |
Efficacy Defined as Change From Baseline on the Investigator Rated DSM-IV Based ADHD Rating Scale, Over the Course of the Day.
Units on a scale range from 0-3 on a scale of severity, with 0 being the least severe item score and 3 being the most severe. The possible range of scores for the scale is 0 (least severe) to 54 (most severe). (NCT00586157)
Timeframe: Baseline and 4 weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| MTS (Drug A) | 14.76 |
| Placebo | 28.33 |
Conners' Adult ADHD Rating Scales (CAARS)
Measures the DSM based ADHD criteria of Inattention and Hyperactivity/Impulsivity. There are 30 items scored 0-3 for a minimum score of 0 (no symptoms) and a maximum score of 90 worst possible symptoms. (NCT00506285)
Timeframe: Double-blind endpoints for MTS and placebo arms
| Intervention | units on a scale (Mean) |
|---|---|
| Scores in MTS Arm | 30.8 |
| Scores in Placebo Arm | 49.5 |
Wender Reimherr Adult Attention Deficit Disorder Scale
This scale measures the 7 domains of the Utah Criteria for Adult ADHD. Total scores run from 0 to 28. Normative samples average below 5. The worst possible score is 28. (NCT00506285)
Timeframe: Double-blind endpoints during MTS and placebo arms
| Intervention | units on a scale (Mean) |
|---|---|
| Scores in MTS Arm | 11.0 |
| Scores in Placebo Arm | 17.9 |
Reviews
2 reviews available for oxybutynin and ADDH
| Article | Year |
|---|---|
Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS).
Topics: Administration, Cutaneous; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2014 |
Drugs for ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-A | 2015 |
Trials
4 trials available for oxybutynin and ADDH
| Article | Year |
|---|---|
Treatment of nocturnal enuresis in children with attention deficit hyperactivity disorder.
Topics: Antidepressive Agents, Tricyclic; Antidiuretic Agents; Attention Deficit Disorder with Hyperactivity | 2007 |
Reliability and Validity of the Before-School Functioning Scale in Children With ADHD.
Topics: Administration, Cutaneous; Attention Deficit Disorder with Hyperactivity; Behavior Rating Scale; Chi | 2018 |
Oppositional defiant disorder in adults with ADHD.
Topics: Adult; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperact | 2013 |
Methylphenidate transdermal system in attention-deficit hyperactivity disorder in adolescents: profile report.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Humans; Methylphenid | 2012 |
Other Studies
2 other studies available for oxybutynin and ADDH
| Article | Year |
|---|---|
Evaluating use of higher dose oxybutynin in combination with desmopressin for refractory nocturnal enuresis.
Topics: Adolescent; Antidiuretic Agents; Attention Deficit Disorder with Hyperactivity; Child; Deamino Argin | 2016 |
First Amphetamine Transdermal Patch Approved for ADHD.
Topics: Administration, Cutaneous; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervo | 2022 |